Clinical Trial Results:
A Phase III, multi-center, randomized, double-blind study to evaluate the efficacy and safety of 50 mg and 100 mg of sufugolix (TAK-013) tablets administered twice daily versus placebo for 12 weeks in subjects with symptomatic endometriosis.
Summary
|
|
EudraCT number |
2004-001721-13 |
Trial protocol |
GB |
Global completion date |
01 Jan 1900
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
14 Oct 2017
|
First version publication date |
14 Oct 2017
|
Other versions |
|
Summary report(s) |
Withdrawn study |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.